PRIMARY ENDPOINT

  • biontech s cancer drug meets primary endpoint in phase 2 trial

    BioNTech's cancer drug meets primary endpoint in Phase 2 trial

    ​The trial met its primary endpoint, with data demonstrating a statistically significant improvement in the overall response rate in patients treated with the mRNA immunotherapy candidate BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimab, compared to a historical control in patients with advanced melanoma, BioNTech said.

Join the community of 2M+ industry professionals

Subscribe to our Daily Newsletter

By continuing you agree to our Privacy Policy & Terms & Conditions

Download ETHealthworld App for Realtime updates

Seamless reading experience. Save your favourite.

Scan to download App

Download ETHealthworld App for Realtime updates of content you follow

  • Seamless reading experience
  • Save your favourite articles
Advertisement
Advertisement